Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30397090 | 1.00 | KMT2A (0.62) | KMT2AMAPK1LMNACFTRKDM4E | |
| Ammonia Solution, Strong SCHEMBL28197882 | 0.98 | KMT2A (0.60) | KMT2AMAPK1LMNACFTRKDM4E | |
| SCHEMBL17138424 | 0.87 | MAPK1 (0.56) | KMT2AMAPK1LMNACFTRKDM4E | |
| SCHEMBL17138423 | 0.87 | MAPK1 (0.56) | KMT2AMAPK1LMNACFTRKDM4E | |
| SCHEMBL1397745 | 0.84 | MAPK1 (0.61) | KMT2AMAPK1LMNAKDM4EL3MBTL1 | |
| SCHEMBL17138392 | 0.84 | MAPK1 (0.53) | KMT2AMAPK1LMNACFTRKDM4E | |
| SCHEMBL17138428 | 0.83 | MAPK1 (0.51) | KMT2AMAPK1LMNACFTRKDM4E | |
| SCHEMBL10328702 | 0.83 | KMT2A (0.62) | KMT2AMAPK1LMNAPOLBGAA | |
| SCHEMBL29664542 | 0.82 | POLB (0.57) | KMT2ALMNAKDM4EL3MBTL1POLB | |
| SCHEMBL5440798 | 0.82 | POLB (0.57) | KMT2ALMNAKDM4EL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340568-A1 | SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250320226-A1 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | VERTEX PHARMA (US) | 2025-10-16 | — | — | US | disclosed |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4192829-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025090792-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-04-17 | — | — | US | disclosed |
| US-12269831-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-08 | — | — | US | disclosed |
| US-20080275239-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2008-11-06 | — | — | US | disclosed |
| US-20080207905-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080207905-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080200678-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200678-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2008-08-21 | — | — | US | disclosed |
| EP-1156048-B1 | Heteroaroyl-isoxazoles and their use as herbicides | BAYER AGRICULTURE LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| EP-0588357-B1 | Isoxazoles derivatives and their use as herbicides | AVENTIS AGRICULTURE LTD (GB) | 2002-06-12 | — | — | EP | disclosed |
| EP-1156048-A1 | Heteroaroyl-isoxazoles and their use as herbicides | RHONE-POULENC AGRICULTURE LTD. (GB) | 2001-11-21 | — | — | EP | disclosed |
| EP-0588357-A1 | Isoxazoles derivatives and their use as herbicides | RHONE POULENC AGRICULTURE LTD. (GB) | 1994-03-23 | — | — | EP | disclosed |
| US-4999364-A | Azole derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269831-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | KMT2A 4654/4885MAPK1 3979/4885LMNA 4099/4885 |
| US-20080200678-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | RPS10, SCO2, NFE2L2 | KMT2A 939/4885MAPK1 558/4885LMNA 2984/4885 |
| US-20080275239-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SCO2, NFE2L2, SOD1 | KMT2A 1787/4885MAPK1 437/4885LMNA 2449/4885 |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | KMT2A 1313/4885MAPK1 3687/4885LMNA 2874/4885 |
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | KMT2A 4654/4885MAPK1 3979/4885LMNA 4099/4885 |
| US-20250340568-A1 | SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION | CFTR, SLC26A4, PKD1 | KMT2A 4475/4885MAPK1 4124/4885LMNA 2358/4885 |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | KMT2A 4654/4885MAPK1 3979/4885LMNA 4099/4885 |
| US-20250320226-A1 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | CFTR, PKD1, AQP1 | KMT2A 2491/4885MAPK1 3356/4885LMNA 897/4885 |
| US-20080207905-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | NOX5, PRMT5, SIRT5 | KMT2A 1202/4885MAPK1 1221/4885LMNA 3974/4885 |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | KMT2A 4654/4885MAPK1 3979/4885LMNA 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.